Hrouda D, Perry M, Dalgleish A G
Department of Oncology, St George's Hospital Medical School, London, UK.
Semin Oncol. 1999 Aug;26(4):455-71.
Prostate cancer is one of the leading causes of cancer deaths in the western hemisphere. A number of different gene therapy strategies are currently being evaluated. The ex vivo and many of the in vivo therapies involve stimulating a specific antitumor immune response. Autologous vaccines involving interleukin-2 (IL-2)- or granulocyte-macrophage colony-stimulating factor (GM-CSF)-transduced whole tumor cells showed great promise in animal models. Clinical trials of these and other vaccine strategies are underway. In vivo gene therapies involving the replacement of mutant tumor-suppressor genes, antisense strategies, and the insertion of suicide genes are also being evaluated in prostate cancer.
前列腺癌是西半球癌症死亡的主要原因之一。目前正在评估多种不同的基因治疗策略。体外和许多体内治疗方法都涉及激发特定的抗肿瘤免疫反应。涉及白细胞介素-2（IL-2）或粒细胞-巨噬细胞集落刺激因子（GM-CSF）转导的全肿瘤细胞的自体疫苗在动物模型中显示出巨大潜力。这些以及其他疫苗策略的临床试验正在进行中。涉及替换突变肿瘤抑制基因、反义策略以及插入自杀基因的体内基因治疗也正在前列腺癌中进行评估。
